Special Issue "Clinical Management and Treatment of Chronic Lymphocytic Leukemia (CLL)"
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Hematology".
Deadline for manuscript submissions: closed (25 February 2023) | Viewed by 813
Special Issue Editor
2. Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China
3. Pukou CLL Center, Nanjing, China
4. National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Suzhou, China
Interests: chronic lymphocytic leukemia; BTK inhibitor; BCL2 inhibitor; ibrutinib; venetoclax; drug resistance
Special Issue Information
Dear Colleagues,
The progress of novel agents in the treatment of chronic lymphocytic leukemia (CLL) is remarkable. The advent of the first-in-class BTK inhibitor ibrutinib dramatically improved the outcomes of patients with CLL. The second-generation BTK inhibitors, including acalabrutinib, zanubrutinib, and orelabrutinib, show similar efficacy and potentially improved safety profiles. However, resistance to BTK inhibitors occurs in a proportion of patients, mostly due to BTK 481 mutations. The noncovalent BTK inhibitor pirtobrutinib does not bind to BTK C481 and could induce significant responses in those patients who have developed resistance to covalent BTK inhibitors. BCL2 inhibitors are also important drugs for treating CLL patients. The efficacy of BCL2 inhibitors is remarkable in CLL patients, including those who relapse after treatment with BTK inhibitors. The combination of BTK inhibitors with BCL2 inhibitors or chemoimmunotherapy results in high rates of undetectable minimal residual disease in the bone marrow and a complete response, providing fixed-duration treatments for CLL patients. In this Special Issue, we welcome authors to submit papers on the clinical advance of novel agents in CLL.
Prof. Dr. Jian-Yong Li
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- chronic lymphocytic leukemia
- BTK inhibitor
- BCL2 inhibitor
- ibrutinib
- venetoclax
- drug resistance
